Brotizolam radioimmunoassay: development, evaluation, and application to human plasma samples.
A radioimmunoassay for the determination of the hypnotic agent brotizolam (11) was developed. With this procedure, an antiserum was used which was obtained from rabbits immunized with the hapten 10 (We 934) covalently bound to bovine serum albumin and tritium-labeled brotizolam as the radioligand. Compound 10 represents a structural analogue of brotizolam: the bromine was replaced by a carboxyethyl group. By such manipulation high assay specificity against the primary human metabolites was achieved. The sensitivity limit of the assay was about 100 pg of brotizolam per mL of plasma when 0.1-mL samples were used. The assay showed good accuracy and high precision. Repeated assays after keeping plasma samples frozen for various periods again indicated high precision as well as the stability of the brotizolam molecule under these conditions. Application of the assay to plasma samples of eight subjects who received single oral 0.25-mg doses of brotizolam showed a mean maximum plasma concentration of 4.6 ng of unchanged drug per mL at 0.9 h after administration. The brotizolam plasma concentration declined with a mean elimination half-life of 5.1 h. The pharmacokinetic parameters estimated by RIA agree well with those obtained with other specific brotizolam determination procedures.
D000328:Adult; D001381:Azepines / Q000097:blood*; D004588:Electrophoresis, Cellulose Acetate; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000097:blood*; D007700:Kinetics; D008297:Male; D011863:Radioimmunoassay
D001381:Azepines; D006993:Hypnotics and Sedatives; C020960:brotizolam